Structure of Dovitinib lactate
CAS No.: 692737-80-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Dovitinib lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM.
Synonyms: TKI-258 lactate; CHIR-258 lactate
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 692737-80-7 |
Formula : | C24H27FN6O4 |
M.W : | 482.51 |
SMILES Code : | O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3.CC(O)C(O)=O |
Synonyms : |
TKI-258 lactate; CHIR-258 lactate
|
MDL No. : | MFCD16038905 |
InChI Key : | ZRHDKBOBHHFLBW-UHFFFAOYSA-N |
Pubchem ID : | 135431668 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
HMVEC | 0.04 μM | 72 h | To evaluate the inhibitory effect of Dovitinib on endothelial cell proliferation, results showed that Dovitinib significantly inhibited the proliferation of HMVEC cells at pharmacologically relevant concentrations. | PMC3552726 |
HUVEC | 0.04 μM | 72 h | To evaluate the inhibitory effect of Dovitinib on endothelial cell proliferation, results showed that Dovitinib significantly inhibited the proliferation of HUVEC cells at pharmacologically relevant concentrations. | PMC3552726 |
SMMC7721 | 1.26 ± 0.15 μM | 72 h | To evaluate the inhibitory effect of Dovitinib on HCC cell proliferation, results showed that Dovitinib inhibited the proliferation of SMMC7721 cells at higher concentrations. | PMC3552726 |
MHCC-97H | 0.87 ± 0.17 μM | 72 h | To evaluate the inhibitory effect of Dovitinib on HCC cell proliferation, results showed that Dovitinib inhibited the proliferation of MHCC-97H cells at higher concentrations. | PMC3552726 |
67NR cells | 0.5 μM | 1 h | To examine the effects of NVP-BEZ235 on signaling pathway activity in 67NR cells, results showed that NVP-BEZ235 significantly decreased levels of P-Akt and P-S6, but had no effect on P-Erk. | PMC3672810 |
4T1 cells | 0.5 μM | 1 h | To examine the effects of NVP-BEZ235 on signaling pathway activity in 4T1 and 67NR cells, results showed that NVP-BEZ235 significantly decreased levels of P-Akt and P-S6, but had no effect on P-Erk. | PMC3672810 |
U87MG cells | 3, 4, 5 μM | Dovitinib reduced tumor sphere formation, indicating inhibition of cancer stem cell self-renewal. | PMC5537714 | |
HeLa cells | 2 μM | Dovitinib activates GCN2 by increasing its affinity for ATP | PMC10491595 | |
GB-10 patient cells | 1, 2, 5 μM | 24, 48, 72 h | Dovitinib downregulated HMGA2 and pSTAT3, increased γH2AX levels indicating enhanced DNA damage. | PMC5537714 |
U251 cells | 1, 2, 5 μM | 24, 48, 72 h | Dovitinib downregulated HMGA2 and pSTAT3, increased γH2AX levels indicating enhanced DNA damage. | PMC5537714 |
Rohon-Beard neurons | 6 μM | 48 h | To evaluate the effect of Dovitinib on axon maintenance and cell survival of RB neurons, results showed significant axon loss and cell death. | PMC11026351 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Nude mice | Orthotopic HCC model | Not specified | 25 or 50 mg/kg | Once daily for 14 days | To evaluate the inhibitory effect of Dovitinib on HCC growth and metastasis, results showed that Dovitinib significantly inhibited tumor growth and lung metastasis. | PMC3552726 |
BALB/c mice | 4T1 and 67NR mammary tumor models | Oral | 20 mg/kg | Once daily for 14 days | To evaluate the effects of dovitinib combined with NVP-BEZ235 on tumor growth and metastasis in 4T1 and 67NR models, results showed that the combination caused tumor stasis and significantly reduced lung metastasis. | PMC3672810 |
Mice | MDA PCa 118b bone tumor model | Oral gavage | 40 or 60 mg/kg | Daily treatment for 3 weeks or 7 days | To assess the effect of Dovitinib on tumor volume and bone quality, results showed that Dovitinib significantly reduced tumor volume and improved bone quality. | PMC4407499 |
NOD/SCID mice | Renal cell carcinoma tumorgraft model | Oral gavage | 30 mg/kg | Once daily for ~28 days | Dovitinib significantly inhibited RCC tumorgraft growth, showing greater activity than sunitinib and sirolimus, and was reasonably well tolerated. | PMC3570965 |
Nude mice | LIV31 PDX model | Oral gavage | 30 mg/kg | Daily for 63 days | To evaluate the inhibitory effect of Dovitinib on the growth of LIV31 xenografts. Results showed that Dovitinib significantly inhibited tumor growth, decreased microvascular density, and induced apoptosis. | PMC5119950 |
Zebrafish | Larval zebrafish | Embryo medium | 6 μM | 48 hours | To study the effect of Dovitinib on axon maintenance and cell survival of RB neurons in zebrafish, results showed significant axon loss and cell death. | PMC11026351 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01678105 | Recurrent Adenoid Cystic Carci... More >>noma of the Salivary Glands Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Salivary Gland Cancers ACC Less << | Phase 2 | Completed | - | Canada, Ontario ... More >> Tom Baker Cancer Centre Calgary, Ontario, Canada, T2N 4N2 Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 London Health Sciences Centre London, Ontario, Canada, N6A 4L6 Ottawa Hospital Regional Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Less << |
NCT01223027 | Metastatic Renal Cell Carcinom... More >>a Less << | Phase 3 | Completed | - | - |
NCT01496534 | Solid Tumors ... More >>Bladder Cancer Less << | Phase 1 | Terminated(toxicity of combina... More >>tion of medications) Less << | - | United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less << |
NCT01528345 | Metastatic Breast Cancer | Phase 2 | Terminated(Slow and low enroll... More >>ment) Less << | - | - |
NCT01223027 | - | Completed | - | - | |
NCT01769547 | Advanced Malignant Pleural Mes... More >>othelioma MPM Less << | Phase 2 | Terminated(Stage 1 accrual com... More >>pleted. Study did not proceed to Stage 2 accrual.) Less << | - | Canada, Alberta ... More >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Ottawa General Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Northeast Cancer Centre, Health Sciences North Sudbury, Ontario, Canada, P3E 5J1 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 1X6 Less << |
NCT01528345 | - | Terminated(Slow and low enroll... More >>ment) Less << | - | - | |
NCT01888965 | Colorectal Cancer ... More >> Pancreas Cancer Less << | Phase 2 | Terminated(Adverse Event issue... More >>s.) Less << | - | United States, District of Col... More >>umbia Georgetown University- Lombardi Cancer Center Washington, District of Columbia, United States, 20007 Less << |
NCT01888965 | - | Terminated(Adverse Event issue... More >>s.) Less << | - | - | |
NCT01753713 | Adult Giant Cell Glioblastoma ... More >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor Less << | Phase 2 | Completed | - | United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less << |
NCT01680796 | Multiple Myeloma | Phase 1 | Withdrawn(The target drug, dov... More >>itinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma.) Less << | - | - |
NCT01791387 | Clear Cell Renal Cell Carcinom... More >>a Less << | Phase 2 | Unknown | June 2015 | New Zealand ... More >> Auckland Hospital Auckland, New Zealand, 1142 Less << |
NCT01484041 | Breast Cancer | Phase 1 Phase 2 | Terminated(Decision by company... More >> to cease development of dovitinib) Less << | - | United States, District of Col... More >>umbia Georgetown Lombardi Comprehensive Cancer Center Washington, District of Columbia, United States, 20007 Less << |
NCT01484041 | - | Terminated(Decision by company... More >> to cease development of dovitinib) Less << | - | - | |
NCT01548924 | Solid Tumors | Phase 1 | Terminated(Drug toxicity) | - | Spain ... More >> Hospital Universitario de Bellvitge Hospitalet de Llobregat, Barcelona, Spain, 08907 Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain, 28049 MD Anderson Cancer Centre Madrid, Spain Less << |
NCT01831726 | Tumor Pathway Activations Inhi... More >>bited by Dovitinib Less << | Phase 2 | Completed | - | - |
NCT01753713 | - | Completed | - | - | |
NCT01232296 | Hepatocellular Carcinoma | Phase 2 | Completed | - | China, Jiangsu ... More >> Novartis Investigative Site Nanjing, Jiangsu, China, 210002 China, Shanxi Novartis Investigative Site Xi'an, Shanxi, China, 710032 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310016 China Novartis Investigative Site Beijing, China, 100039 Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Novartis Investigative Site Shatin, New Territories, Hong Kong Japan Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Yokohama-city, Kanagawa, Japan, 232-0024 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 03722 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 110 744 Novartis Investigative Site Seoul, Korea, Republic of, 136-705 Singapore Novartis Investigative Site Singapore, Singapore, 308433 Taiwan Novartis Investigative Site Taipei, Taiwan, ROC, Taiwan, 112 Novartis Investigative Site Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305 Novartis Investigative Site Taichung, Taiwan, 40705 Novartis Investigative Site Taipei, Taiwan, 10048 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Bangkok, Thailand, 10700 Novartis Investigative Site Chiang Mai, Thailand, 50200 Novartis Investigative Site Khon Kaen, Thailand, 40002 Novartis Investigative Site Songkla, Thailand, 90110 Less << |
NCT02065323 | Prostate Cancer | Phase 2 | Withdrawn(Terminated due to bu... More >>dgetary considerations and length of development.) Less << | - | United States, Nevada ... More >> Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89148 Less << |
NCT01232296 | - | Completed | - | - | |
NCT01831726 | - | Completed | - | - | |
NCT01994590 | Prostate Cancer | Phase 2 | Terminated(Sponsor stopped sup... More >>plying study drug) Less << | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02116803 | Solid Tumors | Phase 2 Phase 3 | Completed | - | United States, Nevada ... More >> Novartis Investigative Site Las Vegas, Nevada, United States, 89169 United States, New York Novartis Investigative Site Bronx, New York, United States, 10467-2490 Austria Novartis Investigative Site Salzburg, Austria, 5020 Belgium Novartis Investigative Site Wilrijk, Belgium, 2610 Denmark Novartis Investigative Site Copenhagen, Denmark, DK-2100 Italy Novartis Investigative Site Pavia, PV, Italy, 27100 Novartis Investigative Site Torino, TO, Italy, 10153 Japan Novartis Investigative Site Osaka-city, Osaka, Japan, 545-8586 Spain Novartis Investigative Site Palma De Mallorca, Islas Baleares, Spain, 07120 Less << |
NCT01719549 | Gastric Cancer | Phase 2 | Completed | - | Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Less << |
NCT01514526 | Adrenocortical Carcinoma | Phase 2 | Completed | - | Spain ... More >> Complejo Hospitalario Universitario de Santiago Santiago de Compostela, A Coruña, Spain, 15706 Hospital Universitario Fundación de Alcorcón Alcorcón, Madrid, Spain, 28922 Hospital del Mar Barcelona, Spain, 08003 Hospital Universitario Reina Sofía Córdoba, Spain, 14004 Hospital Universitario Central de Asturias Oviedo, Spain, 33006 Complejo Hospitalario de Navarra Pamplona, Spain, 31008 Fundación Instituto Valenciano de Oncología Valencia, Spain, 46009 Less << |
NCT01478373 | Gastrointestinal Stromal Tumor... More >>s Less << | Phase 2 | Completed | - | Finland ... More >> Novartis Investigative Site HUS, Finland, FIN-00029 France Novartis Investigative Site Bordeaux, France, 33076 Novartis Investigative Site Lille Cedex, France, 59020 Novartis Investigative Site Lyon Cedex, France, 69373 Novartis Investigative Site Reims, France, 51092 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Essen, Germany, 45147 Italy Novartis Investigative Site Milano, MI, Italy, 20133 Novartis Investigative Site Roma, RM, Italy, 00168 Novartis Investigative Site Candiolo, TO, Italy, 10060 Novartis Investigative Site Torino, TO, Italy, 10153 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Hospitalet de LLobregat, Catalunya, Spain, 08907 Novartis Investigative Site Palma De Mallorca, Islas Baleares, Spain, 07120 Novartis Investigative Site Barcelona, Spain, 08041 Less << |
NCT01478373 | - | Completed | - | - | |
NCT01266070 | Von Hippel-Lindau Syndrome | Phase 2 | Terminated(Trial met toxicity ... More >>stopping rule) Less << | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01440959 | Gastrointestinal Stromal Tumor... More >>s Less << | Phase 2 | Completed | - | Korea, Republic of ... More >> Asan Medical Center, University of Ulsan College of Medicine Seoul,, Korea, Republic of, 138-736 Less << |
NCT00790426 | Urothelial Cancer | Phase 2 | Completed | - | - |
NCT01440959 | - | Completed | - | - | |
NCT02116803 | - | Completed | - | - | |
NCT01262027 | Breast Cancer | Phase 2 | Active, not recruiting | December 2017 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01596647 | Advanced Solid Tumors, Excludi... More >>ng Breast Cancer Less << | Phase 1 | Completed | - | United States, Kansas ... More >> University of Kansas Cancer Center Medical Center Kansas City, Kansas, United States, 66160 United States, Michigan Henry Ford Hospital Henry Ford Detroit, Michigan, United States, 48202-2689 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Nevada Comprehensive Cancer Centers Las Vegas, Nevada, United States, 89169 United States, New Jersey Cancer Institute of New Jersey Dept of Cancer Institute of NJ New Brunswick, New Jersey, United States, 08901 Less << |
NCT01262027 | - | Active, not recruiting | - | - | |
NCT00243763 | Multiple Myeloma | Phase 1 | Terminated | - | United States, Arizona ... More >> Mayo Clinic - Arizona Scottsdale, Arizona, United States, 85259 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic - Minnesota Rochester, Minnesota, United States, 55905 Less << |
NCT00279773 | Acute Myeloid Leukemia | Phase 1 | Terminated(Study was stopped d... More >>ue to time dependent drug accumulation) Less << | - | United States, Texas ... More >> The University of Texas, M.D. Anderson Cancer Center Houston, Texas, United States, 77020 Less << |
NCT01700270 | Advanced Solid Tumors, Excludi... More >>ng Breast Cancer Less << | Phase 1 | Completed | - | United States, New York ... More >> Montefiore Medical Center Montefiore Medical Center (SC) Bronx, New York, United States, 10467 United States, Texas Cancer Therapy & Research Center / UT Health Science Center SC San Antonio, Texas, United States, 78229 Denmark Novartis Investigative Site Copenhagen, Denmark, DK-2100 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Switzerland Novartis Investigative Site Chur, Switzerland, 7000 Novartis Investigative Site Genève, Switzerland, 1211 Less << |
NCT01524692 | - | Completed | - | - | |
NCT00958971 | Metastatic Breast Cancer | Phase 2 | Completed | - | - |
NCT01266070 | - | Terminated(Trial met toxicity ... More >>stopping rule) Less << | - | - | |
NCT00831792 | Prostate Cancer | Phase 2 | Completed | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01058434 | Relapsed or Refractory Multipl... More >>e Myeloma Less << | Phase 2 | Completed | - | - |
NCT01417143 | Adenoid Cystic Carcinoma | Phase 2 | Completed | - | Korea, Republic of ... More >> Department of Internal Medicine, Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Less << |
NCT00303251 | Melanoma | Phase 1 Phase 2 | Completed | - | United States, Kentucky ... More >> James Graham Brown Cancer Center Louisville, Kentucky, United States, 40202 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Houston, Texas, United States, 77030 Less << |
NCT01270906 | Neoplasms Can... More >>cer Tumors Less << | Phase 1 | Terminated | - | United Kingdom ... More >> Novartis Investigative Site Glasgow, United Kingdom Novartis Investigative Site Sutton, United Kingdom Less << |
NCT02048943 | Duct Cell Adenocarcinoma of th... More >>e Pancreas Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Withdrawn(Lack of funding) | - | United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less << |
NCT00715182 | Advanced/ Metastatic Renal Cel... More >>l Cancer Less << | Phase 1 | Completed | - | United States, California ... More >> Novartis Investigative Site San Francisco, California, United States United States, North Carolina Novartis Investigative Site Durham, North Carolina, United States, 27710 United States, Washington Novartis Investigative Site Seattle, Washington, United States, 98109-1023 France Novartis Investigative Site Bordeaux Cedex, France, 33075 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site München, Germany, 81675 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3075 EA Spain Novartis Investigative Site Madrid, Spain, 28041 Taiwan Novartis Investigative Site Taipei, Taiwan, ROC, Taiwan, 112 Novartis Investigative Site Taichung, Taiwan, 40705 Novartis Investigative Site Taipei, Taiwan, 10002 Less << |
NCT01443481 | Solid Tumors ... More >>Hepatic Impairment Less << | Phase 1 | Completed | - | United States, California ... More >> University of California at Los Angeles Dept. of UCLA (4) Los Angeles, California, United States, 90095 United States, North Carolina Duke University Medical Center DUMC Durham, North Carolina, United States, 27710 United States, Texas Cancer Therapy & Research Center / UT Health Science Center SC San Antonio, Texas, United States, 78229 Belgium Novartis Investigative Site Gent, Belgium, 9000 Germany Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Italy Novartis Investigative Site Milano, MI, Italy, 20133 Novartis Investigative Site Rozzano, MI, Italy, 20089 Novartis Investigative Site Verona, VR, Italy, 37126 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Novartis Investigative Site Maastricht, Netherlands, 5800 Singapore Novartis Investigative Site Singapore, Singapore, 119228 Less << |
NCT01421004 | Advanced Solid Tumors ... More >> Excluding Breast Cancer Less << | Phase 1 | Completed | - | United States, California ... More >> City of Hope National Medical Center SC-2 Duarte, California, United States, 91010-3000 University of California at Los Angeles UCLA LeConte Location Los Angeles, California, United States, 90095 University of California San Francisco UCSF (SC) San Francisco, California, United States, 94101 United States, Florida Florida Cancer Specialists Sarasota Office Fort Myers, Florida, United States, 33901 United States, Illinois Rush University Medical Center Rush 3 Chicago, Illinois, United States, 60612 United States, Missouri Washington University School of Medicine SC St. Louis, Missouri, United States, 63110 United States, New York Montefiore Medical Center Montefiore Medical Center (SC) Bronx, New York, United States, 10467 United States, Oklahoma University of Oklahoma Health Sciences Center OUHSC - SC Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232-1305 United States, Tennessee Sarah Cannon Research Institute Sarah Cannon Research (SC) Nashville, Tennessee, United States, 37203 United States, Texas Sammons Cancer Center - Texas Oncology SC-2 Dallas, Texas, United States, 78246 Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) San Antonio, Texas, United States, 78229 United States, Utah University of Utah / Huntsman Cancer Institute Huntsman Salt Lake City, Utah, United States, 84112 United States, Wisconsin University of Wisconsin Univ Wisc Madison, Wisconsin, United States, 53792 Less << |
NCT01379534 | - | Completed | - | - | |
NCT01030055 | Neoplasms Can... More >>cer Tumors Less << | Phase 1 | Completed | - | United States, California ... More >> City of Hope National Medical Center Duarte, California, United States, 91010 University of California at Los Angeles Los Angeles, California, United States, 90095 United States, North Carolina Duke University Medical Center Cancer Dept Durham, North Carolina, United States, 27710 United States, Utah University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less << |
NCT01515969 | Non-small Cell Lung Cancer (NS... More >>CLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Stage IV Less << | Phase 1 | Terminated(Patient safety - Un... More >>acceptable toxicity) Less << | - | United States, California ... More >> Stanford University Stanford, California, United States, 94305 Less << |
NCT01155713 | Neoplasm Canc... More >>er Tumors Less << | Phase 1 | Completed | - | United States, Arizona ... More >> Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service Scottsdale, Arizona, United States, 85258 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Tennessee Sarah Cannon Research Institute Sarah Cannon Research Instit Nashville, Tennessee, United States, 37203 United States, Utah University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less << |
NCT00669097 | Advanced Solid Malignancies | Phase 1 | Completed | - | Netherlands ... More >> Novartis Investigative Site Amsterdam, Netherlands Less << |
NCT01524692 | Adenoid Cystic Carcinoma | Phase 2 | Completed | - | United States, Virginia ... More >> University of Virginia Health System Charlottesville, Virginia, United States, 22908 Less << |
NCT01972750 | First or Second Recurrence of ... More >>Glioblastoma Less << | Phase 1 | Unknown | November 2016 | Germany ... More >> Department of Neurology and Center of Integrated Oncology, University Hospital Bonn Bonn, Germany, 53105 Less << |
NCT01576380 | Adenocarcinoma, Scirrhous ... More >> Linitis Plastica Stomach Neoplasms Stomach Diseases Neoplasms by Site Neoplasms Less << | Phase 2 | Completed | - | Japan ... More >> Novartis Investigative Site Nagoya, Aichi, Japan, 464-8681 Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Matsuyama, Ehime, Japan, 791-0280 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8648 Novartis Investigative Site Takatsuki, Osaka, Japan, 569-8686 Novartis Investigative Site Sunto-gun, Shizuoka, Japan, 411-8777 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0045 Novartis Investigative Site Koto, Tokyo, Japan, 135-8550 Less << |
NCT01497392 | Adenocarcinoma of the Pancreas... More >> Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Completed | - | United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less << |
NCT01379534 | Solid Tumors and Advanced Endo... More >>metrial Cancer Endometrial Cancer Second-line Treatment VEGF Less << | Phase 2 | Completed | - | - |
NCT02108782 | Gastrinoma Gl... More >>ucagonoma Insulinoma Pancreatic Polypeptide Tumor Recurrent Islet Cell Carcinoma Somatostatinoma Less << | Phase 2 | Withdrawn | - | - |
NCT01471548 | Advanced Solid Tumors | Phase 1 | Completed | - | Japan ... More >> Novartis Investigative Site Takatsuki, Osaka, Japan, 569-8686 Novartis Investigative Site Hidaka, Saitama, Japan, 350-1241 Less << |
NCT02720926 | Colorectal Cancer ... More >> Gastric Cancer Less << | Phase 1 | Terminated(Unafavourable toxic... More >>ity profile) Less << | - | Singapore ... More >> National Cancer Centre singapore Singapore, Singapore Less << |
NCT01741116 | Hormone Refractory Prostate Ca... More >>ncer Less << | Phase 2 | Unknown | June 2016 | Korea, Republic of ... More >> Korean Cancer Study Group Recruiting Seoul, Chongro-ku, Korea, Republic of, 110999 Contact: So-Yeon Kang 82-2-3276-3511 datacenter1@kcsg.org Korea University Anam Hospital Recruiting Seoul, Seongbuk-gu, Inchon-ro, Korea, Republic of, 136-705 Contact: Kyong Hwa Park, MD, phD +82-2-920-5983 ext 5980 khpark@korea.ac.kr Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.07mL 0.41mL 0.21mL |
10.36mL 2.07mL 1.04mL |
20.72mL 4.14mL 2.07mL |